RxDoctor Payments Data

Diana Hoppe

Encinitas, CANPI 1114944618

Payments from drug & device makers

$67,688in general payments, 2019–2025

Across 155 payments — averaging $436.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$64K
  • Evofem Biosciences, Inc.$2K
  • Lupin Inc.$600
  • AbbVie$374
  • Therapeuticsmd, Inc.$345
  • Amgen$134
  • plus $686 from 15 others

What the payments were for

  • Consulting fees$6001%
  • Speaking & faculty fees$59,58088%
  • Travel & lodging$4,4757%
  • Food & beverage$3,0014%
  • Education$320%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Estradiol24$5,172
Estradiol (Twice Weekly)Estradiol52$4,772
DottiEstradiol30$2,752
ProgesteroneProgesterone, Micronized55$2,106
Escitalopram Oxalate20$396
NitrofurantoinNitrofurantoin Macrocrystal11$329
ValacyclovirValacyclovir Hcl15$178
Zolpidem Tartrate21$140
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine11$123
Alprazolam27$121
Lorazepam21$112
Levothyroxine Sodium11$73
Diazepam12$28

Paid to pharmacies, not to this prescriber.

Where these figures come from

Is this you, or does something look wrong? →